Carcinoembryonic antigen-related cell adhesion molecule 5-6 readthrough transcript (CEACAM5-CEACAM6 readthrough)

ENSG00000267881 refers to a predicted "readthrough" gene that represents a transcript generated by RNA polymerase continuing into CEACAM6 after transcribing CEACAM5. This gene is not believed to encode a functional, independent protein, and there is currently no evidence that this readthrough transcript results in a biologically relevant molecule, nor is it recognized as a therapeutic target, receptor, or enzyme. Experimental research and clinical literature focus on CEACAM5 and CEACAM6 individually, both of which are cell surface glycoproteins involved in cell adhesion, signaling, and cancer biology, but not on this hypothetical readthrough product[1][2][3][4]. There is no clinical, pharmacological, or functional data specifically associated with ENSG00000267881. Additional context: - CEACAM5 and CEACAM6 are heavily implicated in cancer biology, functioning as cell adhesion molecules and contributing to tumor progression, metastasis, and therapeutic resistance[1][2][3][4]. - "Readthrough" transcripts between gene family members are identified in genomic annotations, but the resulting products are generally not known to be independently functional or clinically relevant unless robustly validated. - No evidence exists for drugs targeting this readthrough transcript, nor is it a recognized biomarker or a targetable receptor itself. If your query pertains to CEACAM5 or CEACAM6 individually, detailed information is available for each as genuine and validated targets. - Classification as a molecular target is not supported; this entry likely reflects a genomic annotation artifact rather than a biologically active gene product. If you require information on the individual, well-studied molecules CEACAM5 or CEACAM6, both have established and distinct roles in oncology. The readthrough between them does not.

Other names

CEACAM5-CEACAM6 readthroughENSG00000267881